"Some day, on the corporate balance sheet, there will be an entry which reads, "Information"; for in most cases, the information is more valuable than the hardware which processes it."

Previous Quote

Unfortunately our stock is somehow not well understood by the markets. The market compares us with generic companies. We need to look at Biocon as a bellwether stock. A stock that is differentiated, a stock that is focused on R&D, and a very-very strong balance sheet with huge value drivers at the end of it.

— Kiran Mazumdar-Shaw